scholarly journals Effectiveness ofCitrusFruits onHelicobacter pylori

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Giuseppina Mandalari ◽  
Carlo Bisignano ◽  
Santa Cirmi ◽  
Michele Navarra
Keyword(s):  
Helicobacter Pylori ◽  
Peptic Ulcer ◽  
Side Effects ◽  
Gastric Carcinoma ◽  
Current Knowledge ◽  
Therapeutic Strategies ◽  
Treatment Regimens ◽  
H Pylori ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

It is known thatHelicobacter pyloriinfection is associated with chronic gastritis, peptic ulcer, and gastric carcinoma. Due to the increased side effects of the treatment regimens and the development of antimicrobial resistance, a number of natural compounds have been tested as potential alternatives. In this review, we will examine the current knowledge on the effect ofCitrusfruits and their derivatives againstH. pylori, highlighting the remaining outstanding questions on the development of novel therapeutic strategies.

Eradication of Helicobacter pylori: the power of nanosized formulations

Nanomedicine ◽  
2020 ◽  
Vol 15 (5) ◽  
pp. 527-542
Author(s):  
Qianyu Zhang ◽  
Wen Wu ◽  
Jinqiang Zhang ◽  
Xuefeng Xia
Keyword(s):  
Helicobacter Pylori ◽  
Antibiotic Resistance ◽  
Peptic Ulcer ◽  
Gastric Carcinoma ◽  
Antibacterial Agents ◽  
Antimicrobial Agents ◽  
Mucosal Barrier ◽  
Harsh Environment ◽  
H Pylori ◽  
Cure Rates

Helicobacter pylori is a pathogen that is considered to cause several gastric disorders such as chronic gastritis, peptic ulcer and even gastric carcinoma. The current therapeutic regimens mainly constitute of a combination of several antimicrobial agents and proton pump inhibitors. However, the prevalence of antibiotic resistance has been significantly lowering the cure rates over the years. Nanocarriers possess unique strengths in this regard owing to the fact that they can protect the drugs (such as antibiotics) from the harsh environment in the stomach, penetrate the mucosal barrier and deliver drugs to the desired site. In this review we summarized recent studies of different antibacterial agents orally delivered by nanosized carriers for the eradication of H. pylori.

Clavulanic Acid in the Scope of Helicobacter pylori Treatment: A Literature Review and Beyond

2020 ◽  
Vol 15 ◽  
Author(s):  
Nasr Alrabadi ◽  
Iyad S. Albustami ◽  
Husam A. Abuhayyeh ◽  
Khaled M. El-Muwalla ◽  
Rama J. Alawneh ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Peptic Ulcer ◽  
Peptic Ulcer Disease ◽  
Clavulanic Acid ◽  
Clinical Studies ◽  
Filamentous Form ◽  
Ulcer Disease ◽  
Treatment Regimens ◽  
Randomized Controlled Studies ◽  
H Pylori

Background: Helicobacter pylori (H.pylori) infection is the most common cause of peptic ulcer disease and it can be associated with many complications including malignancies. In clinical practice, some clinicians may use clavulanic acid (CA) in combination with amoxicillin or other beta-lactams as an addition to the standard treatment regimens. This practice may be made by habitual mistake, non-evidence based hypothetical assumptions, or by prescribing it as an alternative treatment. This review aims to expose the effect of CA against H.pylori infection and to review the possible mechanisms that may contribute to that effect. Methods: A PubMed and Google Scholar literature search was obtained on both pre-clinical and clinical studies related to CA and H.pylori infection. Results: Available clinical studies showed improvement in the eradication of H. pylori by about 10-20% when CA was added to the treatment regimens. This effect for CA could be related to several mechanisms including inhibition of H. pylori growth by binding to penicillin-binding proteins (PBPs), the transformation of H. pylori from the active filamentous form into coccoidal form, induction of the release of dopamine, modulation of immunological response towards H. pylori infection and its relationship with other microbiota. Randomized-controlled studies on patients with resistance H. pylori are needed. Moreover, In_vitro studies to evaluate the mechanisms by which CA may influence H. pylori are warranted. Conclusion: The presented literature suggests potential avenues for the use of CA in the management of peptic ulcer disease and H.pylori infection.

scholarly journals The Effect of Probiotic Supplement as Adjuvant Therapy on Dyspeptic Symptoms and Quality of Life during Helicobacter pylori Eradication Therapy in a Sample of Iraqi Patients with Peptic Ulcer Disease

2018 ◽  
pp. 151-162
Keyword(s):  
Quality Of Life ◽  
Helicobacter Pylori ◽  
Peptic Ulcer ◽  
Side Effects ◽  
Adverse Effects ◽  
Eradication Therapy ◽  
Study Group ◽  
Ulcer Disease ◽  
H Pylori

Infection with Helicobacter pylori (H. pylori) had been associated with development of certain symptoms in addition to the use of standard eradication triple therapy has resulted in the increased incidence of undesirable side effects, which can lead to reduced compliance. Probiotics have been proposed to contribute to their efficacy in increasing H. pylori eradication and decreasing side effects when used together with eradication therapy. This study was intended to minimize the side effects of antibiotics therapy and the symptoms associated with peptic ulcer disease (PUD) and improving patient's quality of life (QOL). This interventional prospective randomized- controlled, open-label study was carried out on 77 patients diagnosed with positive H. pylori infection during the period from September 2017 to April 2018. The incidence and intensity of symptom score that caused by adverse effects of both infection and therapy were highly significantly decrease in terms of epigastric pain, bloating, flatulence, taste disturbance, loss of appetite, nausea, vomiting, and heartburn after 2 months of treatment within each study group correspondingly all domains of the quality of life were significantly improved in all patients after H. pylori eradication within each study group. From the present study concluded that the administra¬tion of probiotics as adjuvant to standard triple therapy may suggest a role in improving the symptoms and reduce the adverse effects accompanying with the eradication therapy for H. pylori thus improving patient's quality of life.

scholarly journals Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.

1996 ◽  
Vol 40 (2) ◽  
pp. 477-480 ◽  
Author(s):  
J Versalovic ◽  
D Shortridge ◽  
K Kibler ◽  
M V Griffy ◽  
J Beyer ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Helicobacter Pylori ◽  
Peptic Ulcer ◽  
23S Rrna ◽  
Treatment Regimens ◽  
Clarithromycin Resistance ◽  
Transition Mutation ◽  
H Pylori ◽  
Domain V ◽  
Ulcer Treatment

Twelve clarithromycin-resistant Helicobacter pylori isolates (100% of resistant isolates examined) from seven different patients each contained an A-->G transition mutation within a conserved loop of 23S rRNA. A-->G transition mutations at positions cognate with Escherichia coli 23S rRNA positions 2058 and 2059 were identified. Clarithromycin-susceptible H. pylori isolates from 14 different patients displayed no polymorphisms in a conserved loop within domain V of 23S rRNA. The study is the first to report mutations in H. pylori associated with resistance to an antimicrobial agent used in established peptic ulcer treatment regimens.

PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol

2018 ◽  
Vol 19 (2) ◽  
pp. 165-176 ◽  
Author(s):  
Yan Wang ◽  
Zhao-Peng Liu
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Maximum Tolerated Dose ◽  
Therapeutic Strategies ◽  
Low Density ◽  
Pcsk9 Inhibitors ◽  
Cvd Risk ◽  
Safety Issues ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

Statins are currently the major therapeutic strategies to lower low-density lipoprotein cholesterol (LDL-C) levels. However, a number of hypercholesterolemia patients still have a residual cardiovascular disease (CVD) risk despite taking the maximum-tolerated dose of statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low-density lipoprotein receptor (LDLR), inducing its degradation in the lysosome and inhibiting LDLR recirculating to the cell membranes. The gain-offunction mutations in PCSK9 elevate the LDL-C levels in plasma. Therefore, PCSK9 inhibitors become novel therapeutic approaches in the treatment of hypercholesterolemia. Several PCSK9 inhibitors have been under investigation, and much progress has been made in clinical trials, especially for monoclonal antibodies (MoAbs). Two MoAbs, evolocumab and alirocumab, are now in clinical use. In this review, we summarize the development of PCSK9 inhibitors, including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), small molecule inhibitor, MoAbs, mimetic peptides and adnectins, and the related safety issues.

Sign in / Sign up

Export Citation Format

Share Document